US Bancorp’s Annovis Bio ANVS Stock Holding History

US Bancorp’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-500	Closed	-$43K	–	4065
2021 Q2	$43K	Buy	+500	New	+$23.1K	﹤0.01%	2739

Other funds holding ANVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WFAG

Wescott Financial Advisory Group Philadelphia, Pennsylvania $1.14B AUM 16.59% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

US Bancorp's ANVS Position: Q3 2021 in Review

US Bancorp sold out of Annovis Bio (ANVS) in Q3 2021, closing a stake of 500 shares — an estimated $43K sold.

US Bancorp first reported a position in ANVS in Q2 2021 and held it in 1 quarter. The position peaked at $43K in Q2 2021. 38 funds tracked by Wall St. Rank hold ANVS as of Q3 2021.

US Bancorp reported no remaining Annovis Bio position as of Q3 2021 after selling out during the quarter.
US Bancorp sold 500 Annovis Bio shares in Q3 2021, an estimated $43K.
US Bancorp first reported a position in Annovis Bio in Q2 2021 and held it in 1 quarter.
US Bancorp's Annovis Bio position peaked at $43K in Q2 2021.
38 funds tracked by Wall St. Rank held Annovis Bio as of Q3 2021.

Based on US Bancorp's 13F filing for Q3 2021, filed 10 Nov 2021.